Xenon Pharmaceuticals Statistics
Share Statistics
Xenon Pharmaceuticals has 76.24M shares outstanding. The number of shares has increased by 1.07% in one year.
| Shares Outstanding | 76.24M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.63% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 73.30M |
| Failed to Deliver (FTD) Shares | 662 |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 2.89M, so 3.79% of the outstanding shares have been sold short.
| Short Interest | 2.89M |
| Short % of Shares Out | 3.79% |
| Short % of Float | 3.94% |
| Short Ratio (days to cover) | 7.75 |
Valuation Ratios
The PE ratio is -16.89 and the forward PE ratio is -12.4.
| PE Ratio | -16.89 |
| Forward PE | -12.4 |
| PS Ratio | 0 |
| Forward PS | 80.6 |
| PB Ratio | 3.32 |
| P/FCF Ratio | -20.41 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Xenon Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.65, with a Debt / Equity ratio of 0.
| Current Ratio | 23.65 |
| Quick Ratio | 23.65 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.2% and return on capital (ROIC) is -22.76%.
| Return on Equity (ROE) | -0.2% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -22.76% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -726.67K |
| Employee Count | 251 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -292.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -13.33% in the last 52 weeks. The beta is 1.25, so Xenon Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | -13.33% |
| 50-Day Moving Average | 40.98 |
| 200-Day Moving Average | 40.53 |
| Relative Strength Index (RSI) | 48.3 |
| Average Volume (20 Days) | 391.77K |
Income Statement
| Revenue | n/a |
| Gross Profit | -167.51M |
| Operating Income | -214.05M |
| Net Income | -182.39M |
| EBITDA | -210.51M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.73 |
Balance Sheet
The company has 148.64M in cash and 10.90M in debt, giving a net cash position of 137.74M.
| Cash & Cash Equivalents | 148.64M |
| Total Debt | 10.90M |
| Net Cash | 137.74M |
| Retained Earnings | -665.14M |
| Total Assets | 835.90M |
| Working Capital | 629.94M |
Cash Flow
In the last 12 months, operating cash flow was -145.33M and capital expenditures -5.62M, giving a free cash flow of -150.94M.
| Operating Cash Flow | -145.33M |
| Capital Expenditures | -5.62M |
| Free Cash Flow | -150.94M |
| FCF Per Share | -2.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.87% |
| FCF Yield | -4.99% |
Analyst Forecast
The average price target for XENE is $55, which is 38.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $55 |
| Price Target Difference | 38.5% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 47.4 |
| Piotroski F-Score | 3 |